Thanks for reaching out. Be sure to check us out on LinkedIn for all of our current news and announcements.
Oops! Something went wrong while submitting the form.
The average lifespan of an S&P 500 company has shrunk from 33 years to just 12. That is not a slow decline. It is an acceleration of corporate mortality that should keep every executive team awake at night. The companies vanishing from the index are not small or poorly managed. They are incumbents that failed to build new revenue streams before their core business eroded beneath them.
For decades, the playbook for growth was straightforward: optimize the core, acquire competitors, expand geographically. But that playbook is breaking down. Markets are converging, technology cycles are compressing, and the cost of standing still has never been higher. The question facing large companies today is not whether they need new sources of revenue, but how to create them without betting the entire enterprise on a single, high-risk transformation.
Venture building offers an answer. And the data suggests it is working.
Most large companies understand the need to diversify. Fewer act on it with the urgency the data demands. A 2024 McKinsey study found that companies allocating at least 20% of their growth capital to building new ventures achieve 2.5 percentage points higher revenue growth than their peers. That gap compounds. Over a decade, it is the difference between market leadership and irrelevance.
The same research revealed something even more striking: new ventures launched in the past five years generated 16% of total enterprise value for the companies that built them. And these are not marginal experiments. Sixty-one percent of those ventures crossed $10 million in annual revenue. The ten largest new ventures built by established companies averaged 1.5 times more revenue than the largest startups operating in comparable markets.
This is not a niche strategy. It is becoming the dominant growth model for forward-thinking enterprises. According to McKinsey, two-thirds of executives expect to engage in venture building in the next 12 months, ahead of M&A (22%) and joint ventures (33%). EY-Parthenon estimates that corporate venture building can help bridge a $9 trillion gap in shareholder value, representing the difference between what markets expect from incumbents and what their current trajectories will deliver.
The instinct for many companies facing revenue concentration risk is to acquire their way into new markets. But M&A has a well-documented failure rate. Integration challenges, culture clashes, and inflated valuations mean that most acquisitions destroy value rather than create it. When you buy a company, you inherit its assumptions, its technical debt, and its organizational inertia.
Internal R&D labs and innovation departments face a different problem. They generate ideas but struggle to commercialize them. The organizational antibodies of a large enterprise, risk committees, budget cycles, consensus-driven decision-making, are designed to protect the core business. They are structurally hostile to the kind of rapid iteration and pivoting that new ventures require.
Venture building, particularly when executed through a corporate venture studio, sits in the productive space between these two extremes. It applies startup methodology, lean experimentation, rapid validation, stage-gated investment, while leveraging the assets that only a large company possesses: brand trust, distribution networks, customer relationships, regulatory expertise, and data.
As we have written before at Highline Beta, this is not about disruption for its own sake. It is about growth innovation: the deliberate, systematic creation of new value in areas adjacent to the core business.
The most successful corporate ventures do not try to compete with startups on their own terms. They compete on terms that startups cannot match. Every large company possesses what we call an unfair advantage: proprietary assets that, when deployed in new contexts, create venture opportunities that independent startups simply cannot replicate.
Ping An Insurance is perhaps the most dramatic example of this principle in action. Starting as a traditional Chinese insurer, Ping An recognized that its massive customer base and data infrastructure could fuel entirely new businesses. The company built Lufax (a wealth management platform), OneConnect (a fintech infrastructure provider serving other financial institutions), and Good Doctor (a healthtech platform with over 400 million users). Today, Ping An's technology ventures generate billions in revenue and have fundamentally transformed the company's risk profile. Its insurance heritage, the customer trust, the regulatory relationships, the data, was the unfair advantage that made each of these ventures possible.
Procter & Gamble Ventures took a different but equally instructive approach. P&G had not launched a new brand that reached $100 million in revenue since Febreze. Through its venture building unit, P&G created Zevo, a plant-powered insect control brand. Zevo became the first new bug control brand to disrupt the market in 50 years. P&G's unfair advantages, deep consumer insight capabilities, retail distribution relationships, and brand-building expertise, gave Zevo a path to scale that no independent startup could have achieved in the same timeframe.
The classic tension in corporate strategy is between exploration and exploitation. Exploitation means doubling down on what works today. Exploration means investing in what might work tomorrow. Most companies over-index on exploitation because the returns are immediate and predictable. Venture building creates a structured mechanism for exploration that does not require the core business to change how it operates.
At Highline Beta, we have seen this play out across industries. When Colgate-Palmolive wanted to explore growth beyond its traditional oral care and personal care categories, we worked with their team to discover and validate six new venture opportunities. The process was not about brainstorming in a conference room. It was a rigorous, evidence-based exploration of adjacent markets where Colgate-Palmolive's brand equity, R&D capabilities, and distribution reach gave it a genuine right to win.
Similarly, when ZX Ventures, the growth and innovation unit of AB InBev, needed to build ventures beyond the core beer business, they partnered with Highline Beta to create a repeatable program for venture building. The key insight was that diversification cannot be a one-time event. It needs to be a capability, an organizational muscle that the company exercises repeatedly. ZX Ventures built a system for continuously identifying, validating, and scaling new ventures adjacent to their core business.
The pattern across these cases is consistent: start with the corporate asset base, identify where those assets create disproportionate value in adjacent markets, validate rapidly with real customers, and scale the winners.
Not all diversification is created equal. The ventures most likely to succeed and to generate meaningful revenue are those that operate in markets adjacent to the core business, close enough to leverage existing capabilities, far enough away to access genuinely new demand pools.
This adjacency strategy is what distinguishes venture building from corporate moonshots. When a company builds a venture in an adjacent market, it benefits from:
The question of what to do with a successful venture once it gains traction is itself a strategic decision. Should it be spun in or spun out? There is no universal answer. The right structure depends on how closely the venture's market, business model, and culture align with the parent company. But having that optionality, being able to choose between integration and independence, is one of the unique advantages of corporate venture building.
The most important shift in corporate venture building over the past several years has been the move from treating it as a project to treating it as a permanent capability. Companies that launch a single venture and then disband the team rarely see lasting impact. Companies that build a venture studio, an institutional capability for continuously identifying and building new businesses, create compounding returns over time.
This is why Harvard Business Review and EY have highlighted the growing phenomenon of corporate venture builders as a distinct organizational model. These are not innovation labs or incubators. They are operating units with dedicated teams, capital, and mandates to build and scale new businesses.
At Highline Beta, we have spent years helping companies build exactly this kind of institutional venture-building capability. The companies that treat venture building as a core competency, not a side project, are the ones that consistently generate new revenue streams. They are not betting on a single venture. They are building a portfolio, and the portfolio approach dramatically improves the odds of producing meaningful financial outcomes.
Revenue concentration is a risk that compounds silently. When 80% or more of your revenue comes from a single product line, a single market, or a single business model, you are one technology shift away from crisis. The companies that disappeared from the S&P 500 did not lack talent or resources. They lacked diversified revenue streams that could sustain them through market transitions.
Venture building is not a guarantee of survival. But it is the most disciplined, evidence-based approach available for creating new revenue in adjacent markets. It respects the realities of corporate governance while importing the speed and customer obsession of the startup world. And the data is increasingly clear: companies that embrace it outperform those that do not.
The question is not whether your company needs new revenue streams. It is whether you will build them before your current ones plateau. The companies that start today will have a portfolio of maturing ventures when they need them most. The companies that wait will be scrambling to acquire their way out of decline, paying premium prices for assets they could have built at a fraction of the cost.
The S&P 500 lifecycle data does not lie. The clock is ticking. The best time to start building new ventures was five years ago. The second best time is now.
